Cargando…

P867: CT103A, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF PHASE 1B/2 STUDY (FUMANBA-1)

Detalles Bibliográficos
Autores principales:	LI, Chunrui, Wang, DI, Song, Yongping, Huang, He, LI, Jianyong, Chen, Bing, Liu, Jing, Dong, Yujun, Hu, Kai, Liu, Peng, Zhang, XI, MI, Jianqing, LI, Zhenyu, Ding, Kaiyang, Xu, Aining, Cai, Songbai, Guo, Jingjing, Gui, Hongyu, Wang, Wen, Qiu, Lugui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431138/ http://dx.doi.org/10.1097/01.HS9.0000970372.45392.b8

Ejemplares similares

A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy
por: Mu, Wei, et al.
Publicado: (2022)

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report
por: Li, Dan, et al.
Publicado: (2022)

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Qu, Xiaoyan, et al.
Publicado: (2022)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
por: Wang, Di, et al.
Publicado: (2023)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
por: Reichman, Avinoam, et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
por: Wang, Di, et al.
Publicado: (2021)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
por: Zhang, Wenli, et al.
Publicado: (2021)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

High antigen density of BCMA: friend or foe to CAR T cells?
por: Gaballa, Mahmoud R, et al.
Publicado: (2022)

Fungal Planet description sheets: 785–867
por: Crous, P.W., et al.
Publicado: (2018)

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results
por: Qin, Chuan, et al.
Publicado: (2023)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
por: Que, Yimei, et al.
Publicado: (2021)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

CMS ECAL Endcap - Integration area (bldg.867)
Publicado: (2007)

Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages
por: Joedicke, Jara J., et al.
Publicado: (2021)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Li, C., et al.
Publicado: (2022)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
por: Liang, Zhiyu, et al.
Publicado: (2022)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
por: Li, Wei, et al.
Publicado: (2023)

Upgrade of magnets in Hall 867 - Magnets to be installed B157
por: Brice, Maximilien
Publicado: (2019)

867. Telehealth and HIV Care During the COVID-19 Pandemic
por: Gudipati, Smitha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m9nh8m9oihv952b3mbighe1lo2